Tumor‐Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer
APMIS · 2026-05 · 134 (5)
DOI: 10.1111/apm.70225 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, online erschienen am 21.05.2026. Verfasst von Mariana Bisarro Dos Reis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. Hauptthemen laut MEDLINE: Fusobacterium nucleatum, Colorectal Neoplasms, Fusobacterium Infections. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Ministry of Labor Campinas, Diretoria Executiva do Fundo Nac. De Sa ú de -Fundo Estadual de Sa úde -Fundes, Funda ç ão de Amparo à Pesquisa do Estado de S ão Paulo.
Abstract (Originalsprache)
Tumor budding (TB) and poorly differentiated clusters (PDCs) are histopathological indicators of invasive potential in colorectal cancer (CRC). Concurrently, Fusobacterium nucleatum ( F. nucleatum ) has emerged as a modulator of CRC progression. The relationship between intratumoral F. nucleatum and aggressive tumor architecture remains unknown. We evaluated 257 stage II primary CRCs. TB and PDC were assessed at the invasive front. Intratumoral F. nucleatum DNA was quantified from FFPE samples using droplet digital PCR. Associations between F. nucleatum load and molecular and clinicopathological features were analyzed. F. nucleatum was detected in 44.4% of tumors, with 19.8% classified as high bacterial load. Tumors with high F. nucleatum had a significantly higher frequency of intermediate‐ and high‐grade PDCs ( p = 0.047), with a specific enrichment for high‐grade PDCs ( p = 0.019). High F. nucleatum load was also associated with microsatellite instability (MSI‐H). No significant associations were observed between F. nucleatum presence or load and 10‐year overall, disease‐free, and cancer‐specific survival. A high F. nucleatum intratumoral burden was associated with aggressive tumor architecture characterized by PDC in stage II CRC. Nevertheless, no impact on long‐term clinical outcomes was observed, indicating that F. nucleatum had limited prognostic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
- Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
- Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
- Department of Epidemiology and Biostatistics, Barretos Cancer Hospital, Barretos, Brazil.
- Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal.
ORCID-Profile: Mariana Bisarro Dos Reis, Rui Manuel Reis
Förderung
- Public Ministry of Labor Campinas
- Diretoria Executiva do Fundo Nac. De Sa ú de -Fundo Estadual de Sa úde -Fundes
- Funda ç ão de Amparo à Pesquisa do Estado de S ão Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Dos Reis, M. B., Reis, M. T., Matsushita, M., Berardinelli, G. N., Cheregatto, T. C., Hirai, W., Teodoro, V., Guimarães, D. P., & Reis, R. M. (2026). Tumor‐Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer. APMIS, 134(5). https://doi.org/10.1111/apm.70225
Vancouver
Dos Reis MB, Reis MT, Matsushita M, Berardinelli GN, Cheregatto TC, Hirai W, et al. Tumor‐Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer. APMIS. 2026;134(5). doi:10.1111/apm.70225
BibTeX
@article{DosReis2026,
author = {Dos Reis, Mariana Bisarro and Reis, Monise Tadin and Matsushita, Marcus and Berardinelli, Gustavo Noriz and Cheregatto, Tatiana Camacho and Hirai, Welinton and Teodoro, Valiana and Guimarães, Denise Peixoto and Reis, Rui Manuel},
title = {Tumor‐Associated Fusobacterium nucleatum and Aggressive Architectural Features in Stage II Colorectal Cancer},
journal = {APMIS},
year = {2026},
volume = {134},
number = {5},
doi = {10.1111/apm.70225}
}
EUVIMED